Skip to main content

Advertisement

Table 2 Patients’ characteristics and clinical information

From: A proteomic profile of synoviocyte lesions microdissected from formalin-fixed paraffin-embedded synovial tissues of rheumatoid arthritis

  RA (n = 15) OA (n = 5)
Age (years) 62.9 ± 10.3 66.2 ± 9.7
Gender, n (% female) 11 (73.3) 5 (100.0)
Disease duration (years) 11.7 ± 9.0 5.7 ± 5.6
Stage (I/II/III/IV) 1/1/11/2  
Class (I/II/III/IV) 1/5/8/1  
DAS28-CRP 3.5 ± 1.1  
CRP(mg/dL) 2.4 ± 2.2  
MMP-3 (ng/mL) 430.8 ± 531.5  
MTX use, n (%) 9 (60.0)  
MTX dose (mg/week) 4.1 ± 3.6  
Oral steroid use, n (%) 7 (46.7)  
Oral steroid dose (mg/day) 1.4 ± 1.7  
Biologics use, n (%) 3 (20.0)  
Sampling site
 Wrist joint, n 3 0
 Elbow joint, n 1 0
 Hip joint, n 1 4
 Knee joint, n 10 1
  1. The values are mean ± SD unless otherwise indicated.
  2. DAS disease activity score, CRP C-reactive protein, MMP-3 matrix metalloproteinase 3, MTX methotrexate.